Clinical Trials Browser

Withdrawn × Lymphoma, B-Cell, Marginal Zone × acalabrutinib × Clear all

NCT04836832 2022-06-07

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone